Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
Turning Point Therapeutics
company
About
Turning Point Therapeutics is a pharmaceutical company that discovers and develops precision medicines for cancer and other diseases.
- 251 - 500
Details
- Last Funding Type
- Private Equity（PE）
- Last Funding Money Raised
- $80M
- Industries
- Biotechnology,Health Care,Pharmaceutical,Therapeutics
- Founded date
- Oct 8, 2013
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. They focus on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating the tumor microenvironment and tumor immunity.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$125M
Turning Point Therapeutics has raised a total of
$125M
in funding over 2 rounds. Their latest funding was raised on
Oct 19, 2018 from a Private Equity（PE） round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 19, 2018 | Private Equity（PE） | $80M | 1 | — | — | Detail |
| May 23, 2017 | Series C | $45M | 1 |
Lilly Asia Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Turning Point Therapeutics is funded by 1 investors.
Lilly Asia Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Lilly Asia Ventures
|
— | Private Equity（PE） |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
